Isomorphic Labs raises $5 billion for AI drug development
Isomorphic Labs, a DeepMind spin-off for AI drug design, has raised $5 billion in Series C funding from Greenoaks, Sequoia Capital, and newly Andreessen Horowitz. The valuation was reportedly targeted at $50 billion according to Bloomberg, but the company has not confirmed it.
Isomorphic Labs, an AI drug discovery platform spun off from Google DeepMind in 2021, has raised $5 billion in a Series C funding round. The round was co-led by Greenoaks and Sequoia Capital, with Andreessen Horowitz joining as a new investor alongside several other new investors. All existing backers of the company also participated, including Alphabet's venture arms (GV and Capital G), Thrive Capital, MGX, Temasek, and the UK Sovereign AI Fund.
Isomorphic Labs is developing an AI engine for drug design that uses a range of simulation AI models examining various areas of chemistry. The company's work builds on DeepMind's AlphaFold model, which predicts the 3D structure of proteins from genetic sequences. According to the company, the program has achieved "positive preclinical results" in oncology and immunology. The company has signed deals with pharmaceutical companies Eli Lilly, Novartis, and Johnson & Johnson.
The new funding follows the $2.1 billion Series B round from May and, according to the company, will be used for further development of the drug design engine as well as expansion into additional areas of medicine. This is the company's first fundraising since founder and CEO Demis Hassabis stepped down from leading DeepMind to focus on drug discovery, moving into the role of chairman at DeepMind. Hassabis and then-DeepMind director of research John Jumper received the Nobel Prize in Chemistry for their work on the AlphaFold model.
Isomorphic Labs has not disclosed its new valuation. Bloomberg reported earlier this month that the company was seeking funding at a $50 billion valuation — this is therefore an unconfirmed figure, not an officially announced value.
Why it matters
The funding shows that investors are putting significant resources into an AI approach to drug discovery that combines simulation models with AlphaFold data and targets clinical trials in oncology and immunology. For the pharmaceutical sector, the existence of partnerships with Eli Lilly, Novartis, and Johnson & Johnson is particularly relevant, as they point to the practical deployment of AI in the early stages of drug development.
Relevant practical impact
What this means
For a business
The funding amount ($5 billion) and the involvement of investors such as Andreessen Horowitz show that capital markets view AI tools for drug design as a sector with high investment potential, which could shape expectations for similar biotech/AI startups as well as partnership opportunities with pharmaceutical companies.
StrategyCheck the original
Event sources
only one source so far · 1 publisher, 1 independent. We count feeds from the same owner only once.